Friday, December 5, 2014

8:30 - 10:00  
MANAGEMENT OF MENOPAUSAL SYMPTOMS 
Capsule
Since the unfortunate universal drop in HT use following the WHI publication in 2002, we have come almost full circle in understanding the benefits of using HT in young, sympotamtic healthy women at the onset of menopause, but the translation to prescription is still lagging. Where do we stand today?
Chairperson
Mark Brincat, Malta
Margaret Rees
, UK
  
Debate: HRT for menopausal women will rebound to pre WHI era
Yes: Serge Rozenberg, Belgium
No: Sven Skouby, Denmark
Discussion

 

Debate: Vaginal application of sex steroids: The future in women's health? What are the limitations?
Yes: Andrea Genazzani, Italy 

No: Alessandra Graziottin, Italy 
Discussion

 

 

10:20 - 11:50
HRT: WHO SHOULD BE TREATED?
Organized by EMAS
Capsule
While HT should probably not be started on older women we still need to have a more precised, personalized way to select the "right treatment to the right early postmenopausal woman". Where are we today?
Chairperson
Margaret Rees, UK
 
HRT: Who should be treated?
Sven Skouby, Denmark
  HRT revised in light of new evidence
Serge Rozenberg, Belgium
  Beneficial actions of progesterone including on the brain
Regine Sitruk-Ware, France 
 

Pharmaceutical interventions at the time of menopause to reduce the incidences of breast cancer
Mark Brincat, Malta 

   

12:10 - 13:40 
NEW COMBINATION IN THE MARKET
Capsule
Should we go back to prescribing HT to climacteric-symptomatic patients, or just combine SERMs and HT to enjoy the best of both worlds?

Chairpersons

Sven Skouby, Denmark
 
Mechanism of action of the estrogens/bazedoxifene
Christian Egarter, Austria 
 
Efficacy and sapfety of conjugated estrogens/bazedoxifene (CE/BZA)
Santiago Palacios, Spain
 
Positioning of estrogens/bazedoxifene in the treatment of menopausal women
Andrea Genazzani, Italy
 
HT and osteoporosis
Robert Langer, USA

   

14:30 - 16:00 
TREATMENT OF MENOPAUSE
Capsule

Aspects of hormonal treatment around menopause

Chairpersons
Herjan Coelingh Bennink, Netherlands
Robert Langer, USA
 
Why don't we give COC users their androgens back?
Rik van Lunsen, Netherlands
 
Sex steroids as anti-aging therapy for the women's brain
Andrea Genazzani, Italy
 
Contraception and menopaue
Alfred Mueck, Germany
 
Menopause, hormones, well-being and sexuality
Michèle Lachowski, France

   

16:30 - 18:00
MANAGING THE MENOPAUSAL SYMPTOMS 
Capsule

Fungal infections of the vaginal tract account for a substantial number of medical consultations and recurrences that are due to mis-diagnosis and imprecise treatments.

Chairpersons Santiago Palacios, Spain
Alfred Mueck
, Germany
 
Vaginal Lactobacilli and biofilm formation
Gary Ventolini, USA
 
Pathogenic biofilms: Leading contibutors to recurrent vaginitis and cystitis
Alessandra Graziottin, Italy
 
Non-hormonal treatment of menopause
Santiago Palacios, Spain

 

Saturday, December 6, 2014

08:30 - 10:00 
OVARIAN CANCER
Capsule Ovarian cancer is among the deadliest gynecological diseases. Can we improve detection and survival by better screening tools?
Chairpersons Richard G. Moore, USA
Adam Rosenthal, UK
 
Pelvic mass risk assessment: Do we need to operate on everyone?
Richard G. Moore, USA
 
BRCA gene mutation: When do we screen and when do we operate?
Adam Rosenthal, UK
 
Ovarian cancer screening in the general population: To screen or not to screen - What is the future?
Ian Jacobs, UK
 
The origin of ovarian cancer
Victor Gomel, Canada

   

 Workshop in HPV and adolescence gynecology

10:20 - 11:50 
HPV SCREENING
Capsule
Cervical cancer can be easily eliminated  by HPV vaccination, so why is this still not universally applied and what are the concerns? A top international expert panel will address all the current issues, questions and misbeliefs
 Chairpersons
Xavier Bosch, Spain
Chris J. Meijer, Netherlands
 
The regulation of HPV screening in Europe: Indication and trends.
Xavier Bosch, Spain
 
Out of 100+ available HPV tests, which are validated for screening/triage
Chris J. Meijer, Netherlands
 
The predictive value of HPV typing in screening vs. cocktail testing and typing as triage
Thomas Iftner, Germany
 
Triage after HPV testing: The current role of cytology and other biomarkers
Quek Swee Chong, Singapore
 
DNA vs. mRNA tests
Thomas Ifner, Germany
 
Self-sampling the new frontier for screening coverage
Elmar Joura, Austria
 
Screening vaccinated women
Xavier Bosch, Spain

   

12:10 - 13:40 
HPV VACCINATION AND COMBINED PROTOCOLS
 Chairpersons
Xavier Bosch, Spain
Jorma Paavonen, Finland
 
How much disease will be avoided in vaccinated cohorts?
Elmar Joura, Austria
 
How much disease is avoided in vaccinated cohorts as recorded from population monitoring?
Jorma Paavonen, Finland
 
Boys and adult male vaccination
Elmar Joura, Austria
 
Substantial issue in vaccinology
Quek Swee Chong, Singapore
 
Vaccine safety
Jorma Paavonen, Finland
 
Integrated preventive approaches for women of all ages
Xavier Bosch, Spain
 
Screening and vaccination in The Nertherlands
Chris J. Meijer, Netherlands

   

14:30 - 16:00 
A MULTIDIMENSIONAL GYNECOLOGICAL CARE OF ADOLESCENTS
Capsule
It is common to trace the origin of some of endocrinopathies and adult gynecological symptoms to the adolescent years: Managing the un-met needs
Chairperson Alessandra Graziottin, Italy
Sven Skouby
, Denmark
 
The adolescent: A patient at risk
Charles Sultan, France
 
Consultation with the adolescent: More than a gynecological examination
George K. Creatsas, Greece
 
Deficiencies in the adolescent: Key supplementations
Santiago Palacios, Spain  

 

16:30 - 18:00 
CONTRACEPTION AND FAMILY PLANNING
Capsule 
Contraception before and after the reproductive years remains a challenge
Chairpersons
Charles Sultan, France 
George K. Creatsas, Greece
 
Adolescence contraception
George Creatsas, Greece 
 
Peri-menopausal use of 17Beta estradiol OC’s
Anne Gompel, France
 
Medical termination of Pregnancy
Aubert Agostini, France